{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 462255663
| IUPAC_name = 4-Amino-5-chloro-2-ethoxy-''N''-<nowiki>[[</nowiki>4-[(4-fluorophenyl)methyl]morpholin-2-yl]methyl]benzamide
| image = Mosapride.svg
| width = 260
| image2 = 3D Mosapride.png

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|mosapride}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA =  
| legal_UK =  
| legal_US =  
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 112885-41-3
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 119584
| IUPHAR_ligand = 242
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 106780
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = I8MFJ1C0BY
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08236
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 60889

<!--Chemical data-->
| C=21 | H=25 | Cl=1 | F=1 | N=3 | O=3 
| molecular_weight = 421.893 g/mol
| smiles = Clc1cc(c(OCC)cc1N)C(=O)NCC3OCCN(Cc2ccc(F)cc2)C3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C21H25ClFN3O3/c1-2-28-20-10-19(24)18(22)9-17(20)21(27)25-11-16-13-26(7-8-29-16)12-14-3-5-15(23)6-4-14/h3-6,9-10,16H,2,7-8,11-13,24H2,1H3,(H,25,27)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = YPELFRMCRYSPKZ-UHFFFAOYSA-N
| synonyms =  
}}

'''Mosapride''' is a [[gastroprokinetic agent]] that acts as a selective [[5-HT4 receptor|5HT<sub>4</sub>]] [[agonist]]. The major active metabolite of mosapride, known as M1, additionally acts as a [[5-HT3 receptor|5HT<sub>3</sub>]] [[antagonist]],<ref name="Tack-2012">{{Cite journal  | last1 = Tack | first1 = J. | last2 = Camilleri | first2 = M. | last3 = Chang | first3 = L. | last4 = Chey | first4 = WD. | last5 = Galligan | first5 = JJ. | last6 = Lacy | first6 = BE. | last7 = Müller-Lissner | first7 = S. | last8 = Quigley | first8 = EM. | last9 = Schuurkes | first9 = J. | title = Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. | journal = Aliment Pharmacol Ther | volume = 35 | issue = 7 | pages = 745–67 |date=Apr 2012 | doi = 10.1111/j.1365-2036.2012.05011.x | PMID = 22356640 | pmc=3491670}}</ref> which accelerates [[gastric emptying]] throughout the whole of the gastrointestinal tract in humans,<ref name="pmid16898619">{{cite journal |vauthors=Odaka T, Suzuki T, Seza A, Yamaguchi T, Saisho H |title=[Serotonin 5- HT4 receptor agonist (mosapride citrate)] |language=Japanese |journal=Nippon Rinsho |volume=64 |issue=8 |pages=1491–4 |date=August 2006 |pmid=16898619 |doi= |url=}}</ref> and is used for the treatment of [[gastritis]], [[gastroesophageal reflux disease]], [[functional dyspepsia]]<ref name="pmid18457463">{{cite journal |vauthors=Curran MP, Robinson DM |title=Mosapride in gastrointestinal disorders |journal=Drugs |volume=68 |issue=7 |pages=981–91 |year=2008 |pmid=18457463 |doi=10.2165/00003495-200868070-00007}}</ref> and [[irritable bowel syndrome]].<ref>{{cite journal | last1 = Mizuta | first1 = Y | last2 = Shikuwa | first2 = S | last3 = Isomoto | first3 = H | last4 = Mishima | first4 = R | last5 = Akazawa | first5 = Y | last6 = Masuda | first6 = J | last7 = Omagari | first7 = K | last8 = Takeshima | first8 = F | last9 = Kohno | first9 = S | date = Nov 2006 | title = Recent insights into digestive motility in functional dyspepsia | url = | journal = Journal of Gastroenterology | volume = 41 | issue = 11| pages = 1025–40 | doi=10.1007/s00535-006-1966-z}}</ref> It is recommended to be taken on an empty stomach (i.e. at least one hour before food or two hours after food).<ref>{{cite journal | last1 = Kato | first1 = S | last2 = Morie | first2 = T | last3 = Yoshida | first3 = N | date = Apr 1995 | title = Synthesis and biological activities of metabolites of mosapride, a new gastroprokinetic agent | url = | journal = Chemical and Pharmaceutical Bulletin (Tokyo) | volume = 43 | issue = 4| pages = 699–702 | doi=10.1248/cpb.43.699}}</ref>

In addition to its [[prokinetic]] properties, mosapride also exerts anti-inflammatory effects on the gastrointestinal tract which may contribute to some of its therapeutic effects.<ref name="pmid21115544">{{cite journal  |vauthors=Tsuchida Y, Hatao F, Fujisawa M, etal |title=Neuronal stimulation with 5-hydroxytryptamine 4 receptor induces anti-inflammatory actions via α7nACh receptors on muscularis macrophages associated with postoperative ileus |journal=Gut |volume=60 |issue=5 |pages=638–47 |date=May 2011 |pmid=21115544 |pmc=3071096 |doi=10.1136/gut.2010.227546 |url=}}</ref> Mosapride also promotes [[neurogenesis]] in the gastrointestinal tract which may prove useful in certain bowel disorders.<ref name="pmid22194416">{{cite journal  |vauthors=Kawahara I, Kuniyasu H, Matsuyoshi H, etal |title=Comparison of effects of a selective 5-HT reuptake inhibitor versus a 5-HT4 receptor agonist on in vivo neurogenesis at the rectal anastomosis in rats |journal=Am. J. Physiol. Gastrointest. Liver Physiol. |volume=302 |issue=6 |pages=G588–97 |date=March 2012 |pmid=22194416 |doi=10.1152/ajpgi.00284.2011 |url=}}</ref><ref name="pmid20146727">{{cite journal  |vauthors=Matsuyoshi H, Kuniyasu H, Okumura M, etal |title=A 5-HT(4)-receptor activation-induced neural plasticity enhances in vivo reconstructs of enteric nerve circuit insult |journal=Neurogastroenterol. Motil. |volume=22 |issue=7 |pages=806–13, e226 |date=July 2010 |pmid=20146727 |doi=10.1111/j.1365-2982.2010.01474.x |url=}}</ref> The neurogenesis is due to mosapride's effect on the 5-HT<sub>4</sub> receptor where it acts as an agonist.<ref name="Goto-2013">{{Cite journal  | last1 = Goto | first1 = K. | last2 = Kato | first2 = G. | last3 = Kawahara | first3 = I. | last4 = Luo | first4 = Y. | last5 = Obata | first5 = K. | last6 = Misawa | first6 = H. | last7 = Ishikawa | first7 = T. | last8 = Kuniyasu | first8 = H. | last9 = Nabekura | first9 = J. | last10 = Takaki | first10 = M | title = In vivo imaging of enteric neurogenesis in the deep tissue of mouse small intestine. | journal = PLOS ONE | volume = 8 | issue = 1 | pages = e54814 | month =  | year = 2013 | doi = 10.1371/journal.pone.0054814 | PMID = 23382976 | pmc=3561410}}</ref>

Its common side effects include dry mouth, abdominal pain, dizziness, headache, insomnia, [[malaise]], nausea, diarrhea and sometimes constipation.<ref name="pmid18457463"/><ref>[http://www.drugsupdate.com/generic/view/328 Mosapride drug information - Drugs Update India<!-- Bot generated title -->]</ref> Unlike some other prokinetic agents, mosapride has little effect on potassium channels, no effect on [[hERG]] transfected cells, and no effect on cardiovascular function that could be detected in tests on humans.<ref name="Tack-2012"/><ref name="Kii-1997">{{Cite journal  | last1 = Kii | first1 = Y. | last2 = Ito | first2 = T. | title = Effects of 5-HT4-receptor agonists, cisapride, mosapride citrate, and zacopride, on cardiac action potentials in guinea pig isolated papillary muscles | journal = J Cardiovasc Pharmacol | volume = 29 | issue = 5 | pages = 670–5 |date=May 1997 | doi =  10.1097/00005344-199705000-00016| pmid = 9213211 }}</ref> Due to the pharmacokinetics of mosapride, it would take 1,000–3,000 times the therapeutic dose to elicit cardiovascular effects.<ref name="Kii-2002">{{Cite journal  | last1 = Kii | first1 = Y. | last2 = Ito | first2 = T. | title = Drug-induced ventricular tachyarrhythmia in isolated rabbit hearts with atrioventricular block | journal = Pharmacol Toxicol | volume = 90 | issue = 5 | pages = 246–53 |date=May 2002 | doi =  10.1034/j.1600-0773.2002.900504.x| pmid = 12076305 }}</ref>

==References==
{{reflist}}

{{Drugs for functional gastrointestinal disorders}}
{{Serotonergics}}

[[Category:Motility stimulants]]
[[Category:Serotonin receptor agonists]]
[[Category:Benzamides]]
[[Category:Morpholines]]
[[Category:Phenol ethers]]
[[Category:Chloroarenes]]
[[Category:Fluoroarenes]]